Hangzhou Tigermed Consulting (300347) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.019x

Based on the latest financial reports, Hangzhou Tigermed Consulting (300347) has a cash flow conversion efficiency ratio of 0.019x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥475.40 Million ≈ $69.57 Million USD) by net assets (CN¥24.71 Billion ≈ $3.62 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Hangzhou Tigermed Consulting - Cash Flow Conversion Efficiency Trend (2009–2025)

This chart illustrates how Hangzhou Tigermed Consulting's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read 300347 current and long-term liabilities for a breakdown of total debt and financial obligations.

Hangzhou Tigermed Consulting Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Hangzhou Tigermed Consulting ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Sulzer AG SW:SUN	0.070x
Grupo Financiero Galicia S.A. BA:GGAL	-0.151x
Chord Energy Corp NASDAQ:CHRD	0.070x
Shanghai Commercial & Savings Bank Ltd TW:5876	0.075x
Immunitybio Inc NASDAQ:IBRX	1.356x
Chemed Corp NYSE:CHE	0.077x
Bank Millennium S.A. WAR:MIL	0.199x
Definity Financial Corp TO:DFY	0.053x

Annual Cash Flow Conversion Efficiency for Hangzhou Tigermed Consulting (2009–2025)

The table below shows the annual cash flow conversion efficiency of Hangzhou Tigermed Consulting from 2009 to 2025. For the full company profile with market capitalisation and key ratios, see Hangzhou Tigermed Consulting market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥24.26 Billion ≈ $3.55 Billion	CN¥1.12 Billion ≈ $163.61 Million	0.046x	+1.12%
2024-12-31	CN¥24.06 Billion ≈ $3.52 Billion	CN¥1.10 Billion ≈ $160.53 Million	0.046x	-3.10%
2023-12-31	CN¥24.45 Billion ≈ $3.58 Billion	CN¥1.15 Billion ≈ $168.35 Million	0.047x	-21.40%
2022-12-31	CN¥22.68 Billion ≈ $3.32 Billion	CN¥1.36 Billion ≈ $198.65 Million	0.060x	-13.38%
2021-12-31	CN¥20.61 Billion ≈ $3.02 Billion	CN¥1.42 Billion ≈ $208.35 Million	0.069x	+23.56%
2020-12-31	CN¥17.86 Billion ≈ $2.61 Billion	CN¥998.68 Million ≈ $146.14 Million	0.056x	-41.47%
2019-12-31	CN¥5.52 Billion ≈ $807.94 Million	CN¥527.56 Million ≈ $77.20 Million	0.096x	-40.13%
2018-12-31	CN¥3.27 Billion ≈ $478.82 Million	CN¥522.24 Million ≈ $76.42 Million	0.160x	+41.95%
2017-12-31	CN¥2.80 Billion ≈ $409.92 Million	CN¥314.97 Million ≈ $46.09 Million	0.112x	+7.79%
2016-12-31	CN¥1.84 Billion ≈ $269.22 Million	CN¥191.91 Million ≈ $28.08 Million	0.104x	-40.14%
2015-12-31	CN¥1.07 Billion ≈ $155.98 Million	CN¥185.73 Million ≈ $27.18 Million	0.174x	+265.93%
2014-12-31	CN¥916.90 Million ≈ $134.17 Million	CN¥43.66 Million ≈ $6.39 Million	0.048x	-53.36%
2013-12-31	CN¥755.14 Million ≈ $110.50 Million	CN¥77.10 Million ≈ $11.28 Million	0.102x	+373.15%
2012-12-31	CN¥694.32 Million ≈ $101.60 Million	CN¥14.98 Million ≈ $2.19 Million	0.022x	-91.86%
2011-12-31	CN¥146.03 Million ≈ $21.37 Million	CN¥38.69 Million ≈ $5.66 Million	0.265x	-4.53%
2010-12-31	CN¥95.79 Million ≈ $14.02 Million	CN¥26.59 Million ≈ $3.89 Million	0.278x	-44.03%
2009-12-31	CN¥44.26 Million ≈ $6.48 Million	CN¥21.95 Million ≈ $3.21 Million	0.496x	--

About Hangzhou Tigermed Consulting

SHE:300347 China Diagnostics & Research

Market Cap

$5.96 Billion

CN¥40.73 Billion CNY

Market Cap Rank

#3188 Global

#459 in China

Share Price

CN¥55.20

Change (1 day)

-2.09%

52-Week Range

CN¥42.31 - CN¥69.86

All Time High

CN¥43083.62